Artax Biopharma is a clinical stage biotechnology company that develops novel treatments for autoimmune diseases.
The lead product, AX-158, is a first-in-class, oral small molecule that inhibits Nck’s binding to the T cell receptor (TCR). Through this novel mechanism, it selectively modulates Nck’s amplification of the TCR signal, resulting in a lower T Cell activation and lower T Cell response.
Location: Cambridge, USA
Sound contact: Casper Breum (Board Director) and Ester Sklarsky (Board Observer)
Old news: Artax expands their SAB with two experts in T-Cell-Mediated Diseases
Read an interview with Joseph Lobacki, CEO: A patient-centric mission for life-changing autoimmune treatments
